(Q36276435)

13 August 2017

1 reference

title

Drugs for exceptionally rare diseases: do they deserve special status for funding? (English)

1 reference

13 August 2017

1 reference

D A Hughes

1

1 reference

13 August 2017

B Tunnage

series ordinal

2

1 reference

13 August 2017

S T Yeo

series ordinal

3

1 reference

13 August 2017

language of work or name

English

0 references

publication date

3 October 2005

1 reference

QJM: An International Journal of Medicine

13 August 2017

published in

1 reference

13 August 2017

volume

98

1 reference

13 August 2017

issue

11

1 reference

13 August 2017

page(s)

829-836

1 reference

Development of Orphan Vaccines: An Industry Perspective

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093/QJMED/HCI128

Clinical trials and rare diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/QJMED/HCI128

Ethical issues in funding orphan drug research and development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/QJMED/HCI128

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/QJMED/HCI128

QALY maximisation and people's preferences: a methodological review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/QJMED/HCI128

Intergenerational equity: an exploration of the 'fair innings' argument

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/QJMED/HCI128

Setting up an outcomes guarantee for pharmaceuticals: new approach to risk sharing in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/QJMED/HCI128

Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/QJMED/HCI128

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/QJMED/HCI128

21 January 2018

Identifiers

DOI

10.1093/QJMED/HCI128

1 reference

13 August 2017

1 reference